Linked Life Data

15780830

Source:http://linkedlifedata.com/resource/pubmed/id/15780830

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-3-22
pubmed:abstractText
Platelets are known to play a pivotal role not only in the formation of arterial thrombosis but also in the progression of atherosclerotic disease. Recent data suggest that these activities of platelets have become enhanced in patients with type 2 diabetes, accounting for many of the cardiovascular complications. Although aspirin is the most commonly used drug to regulate platelet function, many patients do not receive the expected clinical benefit of this drug and do not have the expected inhibition of platelet function, perhaps because of platelet hyperactivity in diabetes. The data suggest that aspirin might be a less than adequate antithrombotic for type 2 diabetes and that alternative therapies (e.g. combinations with clopidogrel or new antithrombotic therapies) are required to effectively manage the prevalent thrombotic complications associated with this disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
190-7
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Aspirin response and failure in diabetic patients with cardiovascular disease.
pubmed:affiliation
Portola Pharmaceuticals Inc, 270 E. Grand Avenue, Suite 22, South San Francisco, California 94080, USA.
pubmed:publicationType
Journal Article, Review